| TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome FG Rücker, RF Schlenk, L Bullinger, S Kayser, V Teleanu, H Kett, ... Blood, The Journal of the American Society of Hematology 119 (9), 2114-2121, 2012 | 740 | 2012 |
| The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML S Kayser, K Doehner, J Krauter, CH Koehne, HA Horst, G Held, ... Blood, The Journal of the American Society of Hematology 117 (7), 2137-2145, 2011 | 546 | 2011 |
| Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group J Krönke, RF Schlenk, KO Jensen, F Tschürtz, A Corbacioglu, VI Gaidzik, ... Journal of Clinical Oncology 29 (19), 2709-2716, 2011 | 502 | 2011 |
| Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation RF Schlenk, S Kayser, L Bullinger, G Kobbe, J Casper, M Ringhoffer, ... Blood, The Journal of the American Society of Hematology 124 (23), 3441-3449, 2014 | 463 | 2014 |
| Structural and kinetic basis for heightened immunogenicity of T cell vaccines JL Chen, G Stewart-Jones, G Bossi, NM Lissin, L Wooldridge, EML Choi, ... The Journal of experimental medicine 201 (8), 1243-1255, 2005 | 321 | 2005 |
| TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group VI Gaidzik, P Paschka, D Späth, M Habdank, CH Köhne, U Germing, ... Journal of clinical oncology 30 (12), 1350-1357, 2012 | 318 | 2012 |
| Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD RF Schlenk, D Weber, W Fiedler, HR Salih, G Wulf, H Salwender, ... Blood, The Journal of the American Society of Hematology 133 (8), 840-851, 2019 | 309 | 2019 |
| The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL C Müller, N Murawski, MHJ Wiesen, G Held, V Poeschel, S Zeynalova, ... Blood, The Journal of the American Society of Hematology 119 (14), 3276-3284, 2012 | 281 | 2012 |
| Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma G Held, N Murawski, M Ziepert, J Fleckenstein, V Pöschel, C Zwick, ... Journal of Clinical Oncology 32 (11), 1112-1118, 2014 | 272 | 2014 |
| Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a … V Poeschel, G Held, M Ziepert, M Witzens-Harig, H Holte, L Thurner, ... The Lancet 394 (10216), 2271-2281, 2019 | 236 | 2019 |
| Secondary genetic lesions in acute myeloid leukemia with inv (16) or t (16; 16): a study of the German-Austrian AML Study Group (AMLSG) P Paschka, J Du, RF Schlenk, VI Gaidzik, L Bullinger, A Corbacioglu, ... Blood, The Journal of the American Society of Hematology 121 (1), 170-177, 2013 | 226 | 2013 |
| Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies S Kayser, M Zucknick, K Doehner, J Krauter, CH Koehne, HA Horst, ... Blood, The Journal of the American Society of Hematology 119 (2), 551-558, 2012 | 200 | 2012 |
| Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT M Neuenhahn, J Albrecht, M Odendahl, F Schlott, G Doessinger, ... Leukemia 31 (10), 2161-2171, 2017 | 192 | 2017 |
| Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab JT Bittenbring, F Neumann, B Altmann, M Achenbach, J Reichrath, ... Journal of Clinical Oncology 32 (29), 3242-3248, 2014 | 180 | 2014 |
| The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA RF Schlenk, E Taskesen, Y van Norden, J Krauter, A Ganser, L Bullinger, ... Blood, The Journal of the American Society of Hematology 122 (9), 1576-1582, 2013 | 180 | 2013 |
| Suboptimal dosing of rituximab in male and female patients with DLBCL M Pfreundschuh, C Müller, S Zeynalova, E Kuhnt, MHJ Wiesen, G Held, ... Blood, The Journal of the American Society of Hematology 123 (5), 640-646, 2014 | 165 | 2014 |
| Use of levoglucosan, potassium, and water-soluble organic carbon to characterize the origins of biomass-burning aerosols RC Urban, M Lima-Souza, L Caetano-Silva, MEC Queiroz, RFP Nogueira, ... Atmospheric Environment 61, 562-569, 2012 | 162 | 2012 |
| Rational development of high-affinity T-cell receptor-like antibodies G Stewart-Jones, A Wadle, A Hombach, E Shenderov, G Held, E Fischer, ... Proceedings of the National Academy of Sciences 106 (14), 5784-5788, 2009 | 154 | 2009 |
| ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group P Paschka, RF Schlenk, VI Gaidzik, JK Herzig, T Aulitzky, L Bullinger, ... Haematologica 100 (3), 324, 2015 | 143 | 2015 |
| Anti-CD16/CD30 bispecific antibody treatment for Hodgkin’s disease: role of infusion schedule and costimulation with cytokines F Hartmann, C Renner, W Jung, L da Costa, S Tembrink, G Held, A Sek, ... Clinical cancer research 7 (7), 1873-1881, 2001 | 132 | 2001 |
